Biography: Robert Schilz, DO
- Director, Lung Transplantation, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
Certifications & Memberships
- Critical Care Medicine - American Board of Internal Medicine
- Pulmonary Disease - American Board of Internal Medicine
Fellowship | Pulmonary/Critical Care
Pulmonary/Critical Care - Yale University School Of Medicine (1993 - 1996)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Cleveland Clinic (1992 - 1993)
Residency | Internal Medicine
Internal Medicine - Cleveland Clinic (1989 - 1992)
Internship | Internal Medicine
Internal Medicine - Sparrow Hospital (1988 - 1989)
Michigan State University College Of Human Medicine (1988)
University Of Wisconsin-Madison (1979)
Dr. Robert Schilz is director of the Pulmonary Vascular Disease Program at University Hospitals Cleveland Medical Center. He is also an Associate Professor at Case Western Reserve University School of Medicine.
Dr. Schilz earned Doctor of Osteopathic Medicine (DO) and Doctor of Philosophy (PhD) degrees from the Michigan State University Medical Scientist Training program. He then completed a Residency and Chief Residency at the Cleveland Clinic in Cleveland, Ohio. He also completed Pulmonary & Critical Care and Research fellowships at Yale University. Prior to joining University Hospitals, Dr. Schilz was on staff at the Cleveland Clinic in Pulmonary and Critical Care Medicine.
For over 25 years, Dr. Schilz has participated in clinical and basic research in the areas of advanced lung diseases and pulmonary hypertension, with numerous publications in the areas of pulmonary hypertension, lung transplantation and advanced lung disease.
Dr. Schilz serves or has served as an advisor or committee member for a number of state, national and international organizations, including the International Society for Heart Lung Transplantation, American College of Chest Physicians, Pulmonary Hypertension Association and the Ohio State Board of Hospitals. He is a past Associate Editor of Advances in Pulmonary Hypertension and reviewer for a number of international journals. He has been consistently named as “One of America’s Best Doctors” since 2005.
Patient Experience Reviews
I could not have better care anywhere. Doctor and staff were wonderful.
Love the nurses and dr. Wouldn't go anywhere else
He is the ONLY doctor I don't mind seeing.***
I was very impressed with Dr. Schilz, the time spent and the explanations.
Good,no problem or complaint
My experience with Dr Schilz has been great along with the wonderful nursing staff ***
Great Dr and staff
Everyone was easy to understand
I was in very good hands with this physician. I continue to be impressed in that almost every employee of UH that I have come in contact with has been exceptionally kind, helpful and professional!
The experience was very informative and explained well.
My experience with Dr. Schilz is always good. He is a wonderful Dr. And he is the only one who found the problem I have. He is phenomenal to say the least.
Dr. Schilz has always been an excellent Physician with my Lung concerns and treatments. He literally saved my life.
Dr Schilz is excellent. In fact one of the best doctors I've ever seen at UH the clinic or anywhere all doctors should be is patient knowledgeable and helpful as Dr.Schilz is
Related Blog Articles
Smoking-related emphysema destroys large sections of lung tissue, leaving them essentially useless. The idea behind this treatment is almost counterintuitive, but can produce dramatic results for a certain group of people.
Little victories – like simply going to the grocery store – are celebrated as part of patient’s second chance at life.
Born with cystic fibrosis, 33-year-old Kara King’s lungs began to rapidly fail after the birth of her son and a double lung transplant was the only treatment option. Learn more about the journey that saved her life.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Robert Schilz disclosed the following Outside Relationships with Industry:
- - Gilead - Consulting
- - SCS Healthcare - Consulting
- - United Therapeutics Corp - Consulting
- - Actelion Ltd. - Honoraria
- - Bayer Corporation - Honoraria
- - Genentech, Inc. - Honoraria